LOS ANGELES, CA / ACCESSWIRE / May 29, 2018 / Onconova Therapeutics, Inc. (NASDAQ: ONTX), a
Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer,
with a primary focus on Myelodysplastic Syndromes (MDS), today announced that it will be presenting at the 8th Annual LD Micro
Invitational on Monday, June 4th at 9:00a PDT / 12:00p EDT at the Luxe Sunset Bel Air Hotel in Los Angeles. Mr. Mark Guerin, Chief
Financial Officer of Onconova, will be giving the presentation and meeting with investors.
An audio webcast of the Presentation will be available for 90 days at the following link http://wsw.com/webcast/ldmicro14/ontx and Presentation slides will be available just prior to the
Presentation at https://onconovatherapeutics.gcs-web.com/events-and-presentations.
"The event is slated to be our largest Invitational to date," stated Chris Lahiji, President of LD Micro. "When the fires caused
the cancellation of our Main Event back in December, we vowed to come back even stronger. This event showcases our firm's ability
to attract the most unique and exciting names in micro-cap."
The conference will feature 230 companies in the small-cap / micro-cap space, and will be attended by over 1,000
individuals.
View Onconova's profile here: https://www.ldmicro.com/profile/ONTX.
Profiles powered by LD Micro - News Compliments of Accesswire.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small
molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova's lead
candidate, is a proprietary Phase 3 small molecule agent, which the Company believes blocks cellular signaling by targeting RAS
effector pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work
against specific cellular pathways that are important in cancer cells. Onconova has three product candidates in the clinical stage
and several pre-clinical programs. Advanced clinical trials with the Company's lead compound, rigosertib, are aimed at what the
Company believes are unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com.
About IV Rigosertib
The intravenous form of rigosertib has been employed in Phase 1, 2, and 3 clinical trials involving more than 800 patients, and
is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with higher-risk MDS, after failure
of hypomethylating agent, or HMA, therapy.
About INSPIRE
The INternational Study of Phase III IV
RigosErtib, or INSPIRE, was finalized following guidance received from the U.S.
Food and Drug Administration and European Medicines Agency and derives from the findings of the ONTIME Phase 3 trial. INSPIRE is a
multi-center, randomized controlled study to assess the efficacy and safety of IV rigosertib in HR-MDS patients who had progressed
on, failed to respond to, or relapsed after previous treatment with an HMA within the first 9 months or nine cycles over the course
of one year after initiation of HMA treatment. This time frame optimizes the opportunity to respond to treatment with an HMA prior
to declaring treatment failure, as per NCCN Guidelines. Following interim analysis in early 2018, the independent Data Monitoring
Committee recommended that the trial continue with an expansion in enrollment to 360 patients based on a pre-planned sample size
re-estimation. Patients are randomized at a 2:1 ratio into two treatment arms: IV rigosertib plus Best Supportive Care versus
Physician's Choice plus Best Supportive Care. The primary endpoint of INSPIRE is overall survival. Full details of the INSPIRE
trial, such as inclusion and exclusion criteria, as well as secondary endpoints, can be found on clinicaltrials.gov
(NCT02562443).
About Oral Rigosertib
The oral form of rigosertib was developed to provide more convenient dosing for use where the duration of treatment may extend
to multiple years. This dosage form may also support many combination therapy modalities. To date, 368 patients have been treated
with the oral formulation of rigosertib. Initial studies with single-agent oral rigosertib were conducted in hematological
malignancies, lower-risk MDS, and solid tumors. Combination therapy of oral rigosertib with azacitidine and chemoradiotherapy has
also been explored. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients
with higher-risk MDS who require HMA therapy. A Phase 1/2 trial of the combination therapy has been fully enrolled and the
preliminary results were presented in 2016. This novel combination is the subject of an issued US patent with earliest expiration
in 2028.
Forward Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of
1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act
of 1995, and involve risks and uncertainties. These statements relate to Onconova Therapeutics, Inc.'s expectations regarding the
INSPIRE Trial and the transactions contemplated by the licensing agreement. Although Onconova believes that the expectations
reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially
different from the results expressed or implied by such forward-looking statements. Onconova has attempted to identify
forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes. These
statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including Onconova's ability
to continue as a going concern, the need for additional financing and current plans and future needs to scale back operations if
adequate financing is not obtained, the success and timing of Onconova's clinical trials and regulatory approval of protocols, and
those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form
10-Q.
Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update
any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect
the occurrence of unanticipated events.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The firm hosts
several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector.
LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.
For those interested in attending, please contact David Scher at david@ldmicro.com or
visit www.ldmicro.com for more information.
Onconova Contact:
Mark Guerin
375 Pheasant Run, Newtown, PA 18940
Email: info@onconova.us
www.onconova.com
SOURCE: Onconova Therapeutics, Inc.
